PREVENTIVE OR THERAPEUTIC AGENT FOR TREATING FIBROSIS

摘要

FIELD: biotechnology.SUBSTANCE: group of inventions relates to biotechnology, particularly to siRNA and its use for treating pulmonary fibrosis and pulmonary cancer. siRNA has full length of 17-23 nucleotides and is targeted at sequence containing 17-23 consecutive bases, selected from a group consisting of bases in positions from 1,285 to 1,318, bases in positions from 1,398 to 1418, bases in positions from 1,434 to 1,463, bases in positions from 1,548 to 1,579, bases in positions from 1,608 to 1,628 , bases in positions from 1,700 to 1,726, bases in positions from 1,778 to 1,798, bases in positions from 1,806 to 1,826 and bases in positions from 1,887 to 1,907 sequence SEQ ID NO: 1.EFFECT: for use in effective inhibition and suppression of expression of gene TGF-β1, in hybridisation.21 cl, 5 dwg, 10 tbl, 9 ex